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Introduction: We describe a new approach to drug 
discovery which joins the technologies of medicinal 
and combinatorial chemistry, allowing selection of the 
most active variant of a lead compound from a large 
(>1012) pool. A small-molecule covalent inhibitor of 
elastase was coupled to a randomized pool of RNA, 
and this assembly was iteratively selected for oligo- 
nucleotide sequences that promote the covalent reac- 
tion of the inhibitor with the human neutrophil elastase 
(hNE) active site. 
Results: Incorporation of the covalent inhibitor into 
the randomized pool increases the second-order rate of 
inactivation of hNE by -15fold; sequences selected from 
this pool show an additional -20-fold increase in activity. 
The relative rate of cross-reaction with another serine 
protease, cathepsin G, was reduced >lOO-fold. Low doses 
of the inhibitor were found to prevent lung damage 
inflicted by human neutrophils in an isolated rat lung 
model of acute respiratory distress syndrome (ARDS). 
Conclusions: This result supports the hypothesis that 
neutrophil elastase is a significant effector of inflamma- 
tory disease. More generally, our findings demonstrate 
that blending small molecules into combinatorial 
libraries is a feasible method of drug discovery. 
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Introduction 
One of the dominant paradigms in drug discovery and 
development is that of medicinal chemistry, in which 
lead compounds are systematically altered by organic 
synthesis to optimize their pharmaceutical properties. 
Because each variant of the lead compound is the 
product of an individual synthetic sequence, only a few 
variants, usually less than 102, can be screened. 
Combinatorial chemistries are intended to accelerate 
drug discovery by the parallel screening or selection of 
lo3 to 1015 candidates. These chemistries, however, 
require the coding, tagging or addressing of the candi- 
dates, a requirement that constrains the chemical and 
conformational space available to the starting libraries 
[l-3].We describe an approach that seeks to access both 
the conformational space made available by combina- 
torial chemistry, and the range of chemical functions 
afforded by medicinal chemistry. Our scheme is outlined 
in Figure 1. A lead inhibitor compound is linked cova- 
lently to a DNA oligonucleotide, and this DNA ‘splint’ 
conjugate is then annealed to the fixed-sequence region 
of a randomized RNA pool. Using the iterative process 
of selection and amplification known as SELEX 
(Systematic Evolution of Ligands by Exponential 
enrichment) [4], those sequences that best promote the 
reaction of the lead compound with the target are iso- 
lated, a process that has been termed ‘blended SELEX’ 
[5]. In effect, the randomized RNA sequence pool 
provides > lOI2 variants of the lead compound from 
which to select the optimal inhibitor. We chose elas- 
tase, a well characterized serine protease, as a target for 
blended SELEX. 
Human neutrophil elastase (hNE) has been implicated 
circumstantially in several inflammatory diseases, includ- 
ing acute respiratory distress syndrome (ARDS), septic 
shock, myocardial ischemia-reperfusion injury, emphy- 
sema and arthritis [6-81. The participation of neutrophils 
and neutrophil elastase is especially compelling in ARDS 
patients who have increased levels of neutrophils and 
oxidatively inactivated anti-proteases in their lungs [9]. 
Numerous elastase inhibitors, including irreversible 
inhibitors, which react with the active-site serine, have 
been described [lo], and are potential lead compounds for 
blended SELEX. We chose a diphenyl phosphonate deriva- 
tive of valine [11,12] as our lead compound. This class of 
inhibitors readily reacts with the elastase active site, but 
both the free inhibitor and the inhibitor-elastase conjugate 
are chemically stable under physiological conditions. 
One of the advantages of SELEX as a drug discovery 
method is that selection conditions can be designed to 
emphasize desirable properties of the winning ligands. 
In this instance, we wished to obtain highly specific 
elastase inhibitors. Accordingly, we performed the selec- 
tions at low concentrations of reactants (‘k,,r/KM con- 
ditions’), to emphasize specificity over reactivity. The 
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selected inhibitors have increased reactivity, but are 
much more specific than the valyl phosphonate lead 
compound, and do not cross-react detectably with 
other serine proteases. 
One of the selected inhibitors was tested in an isolated 
perfused rat lung model of AKIIS. The inhibitor proved 
highly potent and efficacious in preventing neutrophil- 
mediated lung weight gain. Because lung weight gain 
was completely suppressed with a highly specific elastase 
inhibitor, this result implicates hNE as an important 
mediator of lung damage in inflammatory disease. 
Results and discussion 
Using the template 40N7.1 (Fig. 2), we started with a pool 
of 100 pm01 RNA transcribed from 10 pmol randomized 
DNA template. This DNA pool was composed of an 
average of IO copies each of 6 x 10” sequences. The 
RNA pyrimidine nucleotides are 2’-NH,-substituted to 
enhance nuclease resistance [13]. 
The splint oligonucleotide is a synthetic DNA sequence 
that is complementary to the 5’ fixed sequence of- the 
Fig. 1. ‘Blended SELEX’ selection scheme 
for hNE inhibitors. (a) Reaction with 
inhibitor. The valyl phosphonate moiety 
(valP) is shown conjugated to the 5’ 
linker of the DNA splint oligonucleotide, 
which is in turn annealed to the SELEX 
RNA. Nucleophilic attack on the phos- 
phorus center by the elastase active-site 
serine displaces a phenyl group, and 
results in a stable covalent complex 
between elastase and the DNA:valP 
splint. (b) Selection and amplification. 
The jLP RNA:DNA:valP:hNE complexes 
were resolved from unreacted :2p 
RNA:DNA:valP bY electrophoresis 
through 4 %, polyacrylamide, TBE, 
0.05 ‘% SDS, and then recovered from 
the gel by the crush-and-soak method. 
This RNA was amplified by reverse 
transcription, PCR, and transcription by 
T7 RNA polymerase, essentially as 
described 1241. 
SELEX RNA (Fig. 3), and is conjugated to the reactive 
valyl phosphonate moiety (valP) through an amino linker 
at its 5’ end (Fig. 1). We refer to this conjugate as 
IINA:vall?This configuration places the reactive moiety 
physically near the randomized region of the SELEX 
RNA. A six-nucleotide ‘dangling end’ of arbitrary 
sequence was placed at the 5’ end of the splint oligo- 
nucleotide; this allows the selection process to resolve the 
questions of what the length of the splint I)NA-SELEX 
RNA double helix should be, and whether the bases 
near the reactive moiety should be paired or unpaired. 
We selected inhibitors at low concentrations of reactants 
(‘kCSLl conditions’), so that both reactivity and 
binding affinity could contribute to selection. The coil- 
centration of hNE was 20 nM at the beginning of the 
selection, and reduced to 5 nM in the final rounds. The 
extent of the reaction was limited by keeping RNA in a 
IO- to 50-fold excess over hNE. Ten rounds of SELEX 
were performed according to the method outlined in 
Figure 1. The selection was stopped after no substantial 
increases in the second-order rate of inactivation were 
observed for three rounds (Fig. 3). 
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Fig. 2. Sample of selected sequences. The 
sequence of the DNA splint, and the 
fixed-sequence primer-binding regions of 
the RNA are shown at the top. Below are 
the sequences from the RNA random 
regions of the first 10 clones sequenced. 
Shaded areas indicate regions of 
sequence conservation. Underlines indi- 
cate the stems of potential RNA hairpins. 
DNA 3’TCCTGCTACGCCGTCCTGvalP 
RNA ~‘GGGA~~A~G~U;~~~G------~~N------CAGACGACGACGGGGA 
AAAGACAUAUCACU 
GUAUCAAGAUUACU 
GCUGUGAUAUGACU 
AUAAUCUUGGUAUCAAGAUUkJGGGAUGUCG 
10.8 UAUCUACAUGUAGGUCCUAAUCGAAAUCCAGU 
UUAGUCCGUAG 
*liit,lle”.,“.. . . . 
,AUAGCACUAUCUAAACCAGUUGGGGA 
70.11 ACAUAGGUUAAGAUUACCUAACCGAAUUAACAUGCAGC 
10.13 AGUUACUACCGAUACAACCGAAGUCCUCUACCCGUGG 
10.14 UUACUAAGAUUAACAGCUUAGUAUAACAGCCUCCUGUG 
The sequences of 64 RNAs from the round-l 0 pool 
were detcrmined.Txvelve of these are clones, or ‘pseudo- 
clones’, of other sequences. Pseudo-clones are sequences 
that differ at only one or two positions from other 
seq~~ences, and probably arise by errors in replication or 
transcription. Three features of these sequences are note- 
worthy (Fig. 2): (1) the mononucleotide composition 
of the randomized regions is not biased toward G 
(0.33 mol fraction C). PolyG binds and inhibits elastase 
1 06 ..I 
Nucleotide composition of random regions: 
A: 0.278 C: 0.234 G: 0.217 U: 0.271 
Fig. 3. The inactivation rate of hNE by selected inhibitory com- 
plexes increases over several rounds of selection. The second-order 
rate of inactivation of hNE was determined for the unconjugated 
valyl phosphonate (CBz-valP), the DNA splint (DNA:valP) and the 
DNA splint annealed to the pools of RNA from rounds O-IO of 
SELEX, as described in Materials and methods. 
irl IGWO [ 141 and a previous SELEX experiment yielded 
highly (;-rich elastasc ligandr [ 131. (2) Virtually all clones 
(61 /hl) extend the lrngth of the splint helix by two or 
three base-pairs, usually with the sequence ‘CA’ ot 
‘CA’S’. (3) 23/61 clones share the scquenct‘ ‘GUGCC at 
the 3’-end of the random region. lkcauw of the position 
of this sequence, \ve expect that it forms a structure \vith 
the 3’ fixed-sequence region of the RNA. 
Computer-‘assisted RNA f Id’ o mg studies II J] suggest d 
common structural motif. Thirty-ninr of the cloned 
sequences \verc studied; about half (1 Y/30) can form a 
perfect (i.c., without bulges or internal loops) hairpin at 
the 5’ end of the random region.Thesc potential hairpins 
arc immediately 3’ to the RNA-L>NA splint helix, or are 
separated fi-om the splint helix by a U nucleotide. The 
stems of the potential hairpins range in length from tbu~ 
to nine base-pairs, with seven base-pairs being the most 
common length, and there is no apparent sequence coil- 
servation in the stem.The loops of the hairpins range in 
cize from four to seven bases, again mith no apparent 
sequence conservation. The conserved positions of the 
hairpins suggest that they form a coasial stack on the 
splint hclis. 
Inhibition of hNE 
The selected assemblies proved to be potent hNE 
inhibitors. The inhibition of hNE activity (measured by 
hydrolysi\ of a chromogenic peptidc substrate) by the 
RNA10.1 1 :I)NA:vall’ complex is shown in Figure la. 
T\vo paranletcrs are measured in this assay: v,,. the initial, 
rapid equilibrium rate of peptide hydrolysis, and kc,,? l,,,i[, 
the observed rate of enzyme inactivation. Second-order 
rate constants for inactivation (k,,,,C.JK,). derived front 
linear regression of the plots of- kc>,,: II,,IcT versus inhibitor 
concentration (Fig. 4b) are given in Table 1. 
Comparisons of this paraineter show that the sclectcd 
RNAs increase the activity of the valyl phosphonate 
imore than two orders of magnitude as conlpared to the 
free inhibitor, front 1 O4 to > IO” M-’ niiliP’. Coupling of 
the valyl phosphonate to the DNA oligonucleotide. and 
coniplexing this conjugate to random RNA also 
increases inactivation activity. These increases nlay result 
from the affinity of hNE, which is positively charged at 
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Fig. 4. RNA1 0.11 :DNA:valP is a potent inhibitor of hNE activity. 
(a) hNE activity assay. The assay measures the increase in the 
absorbance at 405 nm (Adas) as hNE cleaves a test substrate. 
RNAlO.ll:DNA:valP concentrations: 0 0 nM; 0 10 nM, !J 
20 nM; A  40 nM; A 75 nM; 0 100 nM. (b) Replot of inactiva- 
tion rate versus inhibitor concentration. The slope of the linear 
regression through the replot of kobs inact versus RNA:DNA:valP 
concentration yields the apparent second-order rate constant for 
inhibition, k,nan lpp. 
KI 
neutral pH, for nucleic acids, which are negatively 
charged.The increase in kinacr/KI for the selected ligands 
over that of the starting pool is not large, lO- to %O-fold; 
most SELEX experiments increase binding affinities by 
two to three orders of magnitude 151. The weakness of 
the response to selection may reflect the constraint that 
the RNA bind near the active site of hNE, rather than 
being allowed to find the optimal binding site. 
A complementary assay measures the extent of coupling 
of the DNA:valP conjugate to hNE by gel retardation of 
radioactively labeled splint DNA (Fig. 5a). The stability 
of this coupling under the gel conditions (7 M  urea, 
0.05 %  SDS, 45-50 “C) indicates that the inhibitor forms 
a covalent bond with hNE.The time course of the reac- 
tion shows apparent first-order kinetics, but the extent of 
the reaction is limited to 0.3-0.45 of the total DNA:valP 
depending on the batch of DNA:valI? Because we do 
not observe any loss of coupling after extended incuba- 
tion, we do not attribute incomplete coupling to reversal 
of the inhibitor-hNE bond. Instead, we propose that 
only one stereoisomer of the inhibitor, which is a 
racemic mixture, reacts to a significant extent with hNE. 
In this case a limit of half of the total DNA:valP reacted 
is expected if the two stereoisomers are present in equal 
amount and only one is active.Alternatively, hNE could 
react nonproductively with the inhibitor, degrading it 
without forming a covalent bond. 
When the gel assay is performed at hNE excess, so that 
there is no competition with a peptide substrate, or 
between active and inactive stereoisomers of the 
inhibitor, saturation kinetics are observed (Fig. 5b). 
Michaelian constants for the covalent reaction are given 
in Table 1. The second-order rate constants for this assay 
(2-5 x 10’ M-l mm-‘) are -lo-fold higher than those in 
the peptide hydrolysis assay (2-5 x lo6 M-l min-l). Part 
of this difference can be attributed to correction in the 
gel assay for the fraction of inhibitor that is active, while 
part may be a consequence of the absence of competition 
by inactive complexes for hNE. 
Table 1. Rate and binding constants of inhibitors. 
Inhibitor kinact/Kla K,(Wb kcat (min-l)c K, (MY k,,hAC 
(M-l mid) (M-l min-‘) 
CBz-valP 1.9 (*0.5) x 104 nd nd nd nd 
DNA:vajP 1.6 (rt0.3) x 1 O5 >l o-6 nd nd 3.3 (+0.5) x 10s 
RNA40N7.1 :DNA:valPd 2.9 (iO.1) x 10s >l o-7 b 0.38 (* 0.09) 1.3 (i0.6) x lo-’ 2.9 (i1.4) x 10s 
RNA1 0.2:DNA:valP 5.6 (i0.6) x 1 O6 4 (i5) x lo-* b 3.6 (* 0.6) 1.7 (*0.4) x 1 o-7 2.1 (*0.7) x IO’ 
RNA1 0.6:DNA:valP 5.7 (i2.2) x 106 2 (*2) x 1 O-8 b 3.0 (* 1.2) 1.3 (*l .O) x 1 o-7 2.3 (i2.1) x 10’ 
RNA1 0.11 :DNA:valP 2.4 (~tO.3) x lo6 5 (*6) x 1O-v b 3.4 (i 0.6) 7.1 (*0.4) x 10-s 4.8 (+0.9) x 10’ 
Numbers are the mean (+ standard error). ‘nd’, not done. 
aEnzymatic assay, second-order rate constant for irreversible inactivation. 
$nzymatic assay, reversible competitive inhibition, using the peptide hydrolysis assay for elastase. 
%el retardation assay, rate constants for covalent complex formation. 
dRandom RNAs from the starting pool conjugated to DNA:valP 
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Fig. 5. Michaelian rate constants can be determined for the cova- 
lent reaction oi DNA:valP with hNE. (a) Redction of splint with 
hNE. Lane 1, no hNE control: Lane 2, 10 nM hNE reacted ior 
10 s; Lane 3, 10 nM hNE reacted for 20 s. (b) Evaluation of rate 
constants. Values of k,,,,, ior each concentration of hNE were 
replotted and fitted to the Michaelis-Menten equation for the 
starting RNA pool iRNA40N7.1; 7) and for an inhibitor selected 
after IO rounds of SELEX (RNA1 0.1 1; 0). 
C:onip,~risoll of kcrt values ofsclecteci clones with those 
of the starting po;l (Table 1) shows that selection acted 
to incre,w kc ,I b\, a factor of J- to IO-fold. 13ccause L , 
thv inhibitor re,lcts \I-ith hNE to form J dead-tmd 
co111ples, kL. ,t mu5t represent d step dt or before cova- 
lent bond fo’rm,ltion.Th~ selection therefore must have 
send to increase the rate of one or iiiorc of- thrw 
steps. K, vc~lues LVC’I-c not ci gnit?c,iiltly ~-educed by tlic 
selection, Lvhich might indicate thdt binding affinity to 
hNE \VJS not increased. Increases in the rate of cova- 
Icnt bond t‘ormation could cause increases in K, that 
\vouId m,lsk tightu binding by thr selected RNAs, 
ho\\ ever. Analysis of reversible binding and inhibition 
(b&I\\) indicate that wlcctcd ligands do exhibit 
incrczd affinity fzr IINE. 
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Non-covalent competitive inhibition 
The selected assemblies x-e competitive inhibitors of 
hNE. The parameter for the initial velocity of peptidc 
hydrolysis. v,,, can be used to evduate rapid equilibrium 
re\rcrsiblc inhibition of hNE by the I<NA:I3NA:vall’ 
complese~. We determind the v,lluer of the MichaeliCln 
parameters V !“,!\ Jpp md KM ‘1pp for peptide hydrolysis dt ,I 
series of inhlbltor C(~IlC~‘Iltratloni; (Fig. 0). The appxcnt 
peptidc K,%! is increased by the inhibitor, where,ls there is 
no significClnt effect on Clpparent peptide VlliIx, bcha\.ior 
that is consistent m,ith f~dly competitive inh’ibition. No 
significant eff>ct5 011 V lil.,\ Or Kv \vc‘rc observd for the 
random RNA4ON7.1 :l>NA:vall’ complex, or for the 
l>NA:valP conjugate ~lonr. K, values for reversible inh- 
bition a-e reported in Table 1 .Thew values. which should 
correspond to thr quilibriuni dissociation c‘ointxits of 
the inhibitors. arc‘ of the order of 1 OP M. 
Specificity 
We seltxted hNE inhibitors m&r kc,T/K, conditions 
nith the espect,ltion that the winn& ligands \vould 
show high specificity for hNE. We tested this espectatiou 
by drttxniiiiiiig cross-reactivity with cathepsiii G, ,i 
scriiie protr,isr that has substrate specificity similar to 
hNE, and, like hNE, is positively chxged ‘it nrutrd pH. 
Figure 7 conlpare~ imctivdoll of hNE or c‘lthrpsin (; 
by free vdyl phosphomte or selrcttd l<NA:l>NA:\dP 
inhibitors. The st‘cond-order rate constmt for Inxti\rCl- 
tim by free vnlyl phosphonate is only four-fold less for 
cC~thepsin G thm for hNE. 111 contrast, innctivatiotl of 
cathepsin (; by the I<NA:I>NA:vall’ conlplewe~ is LIII~C- 
tectable. md is dt lext -COO-fold lw thaii the ratr ofinx- 
tivation of hNE.The SELEX proces ha\ therefore act4 
to potentiate the reaction of the vdyl phosphoriatc 
moiety with hNE at low concentrations ill <I specific 
manner. mithout making it gcwcrdly more re,lcti\.e. 
Although our inhibitors do not inactivate cathepsin C;. 
they do displq rc\usible pxti,ll inhibition ‘It high con- 
8~10.~ 
6~10-~ 
4x10-4 
2x10-4 
0x100 
[RNA1 0.11 :DNA:valP], M 
Fig. 6. Reversible, competitive inhihltion by RNA:DNA:valP assem- 
blies. Apparent K,$, (0) and IA/,,,,, (~3) values for the elastase 
peptide substrate in the presence of RNAIO.l 1:DNA:vdlP dre 
shown. The x intercept oi a linear regression of K,, .l,),) versus 
inhibitor concentration yields the negative of the K, value for 
reversible competitive inhibition (Table 1). 
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[Inhibitor], M  
Fig. 7. RNA:DNA:valP complexes specifically inhibit hNE activity. 
0 RNA1 0.2:DNA:valP; 0 RNA1 0.14:DNA:valP; Cl CBz-valP. 
(a) hNE inactivation. Assays were performed as described in 
Materials and methods. (b) Cathepsin C inactivation. Assays and 
analysis similar to those described for hNE were performed for 
cathepsin C. Cathepsin G (Calbiochem) was at 40nM, and its 
substrate (N-methoxysuccinyl Ala-Ala-Pro-Phe p-nitroanilide, 
Calbiochem) was at 0.2 mM.  
centrations.Thrombin, another serine protease, is also not 
inactivated by our inhibitors (data not shown). 
Structural basis of hNE-RNA interaction 
Elastase is a highly positively charged protein at physio- 
logical pH, and is likely to associate with polyanions such 
as RNA through favorable ionic interactions. Poly- 
guanylic acid inhibits hNE, possibly by a competitive 
mechanism, and this inhibition is salt-sensitive [ 141. 
Salmon sperm DNA appears to be a partial non- 
competitive inhibitor, and also shows salt-sensitivity [I 61. 
Irreversible inhibition by selected RNA:DNA:valP 
assemblies is also highly salt-sensitive (Fig. 8), with the 
rate of inactivation reduced to background levels at 
1200 mM total Na’. The SELEX-derived ligands 
reported here therefore share salt-sensitivity with the 
non-specific nucleic acids, suggesting that all of these 
nucleic acids bind to hNE through favorable ionic inter- 
actions. Elastase has a patch or band of arginine residues 
[ 171, constituting a likely binding site for nucleic acids. 
Given the general ability of nucleic acids to bind to 
and inhibit hNE, one may ask whether the RNA 
sequences were selected merely on the basis of their 
ability to associate stably with the DNA:valP splint. 
Figure 9 shows thermal melting data for complexes 
between the DNA:valP splint and either unselected 
RNA, or RNA1 0.11. Two observations can be made 
concerning this data. First, the TI,, of the 
RNA40N7.1:DNA:valP helix (50°C) is well above the 
temperature at which selections were done (37°C). 
Since the equilibrium between melting and annealing 
shifts towards annealing by a factor of 10 for every 3 “C 
below the T,,l, only a tiny fraction of the starting pool 
was not annealed to the DNA:valP oligonucleotide. It 
is therefore unlikely that sequences were selected for 
their more stable association between the RNA and 
the DNA:valP oligonucleotide. Second, a substantial 
(4-7°C) increase in T,,, may be due to the 5’ CA 
sequence which extends the helix by two base pairs 
(Fig. 2). Because this sequence confers only an incre- 
mental increase in stability at the experimental tem- 
perature, it was probably selected through its effects on 
the stereochemistry of the complex, for instance, 
by shortening the six-base ‘dangling end’ to four 
bases (Fig. 2). 
Truncation experiments, in which portions of the 3’ end 
were removed, show that sequences distant from the 
RNA10.2-DNA:valP double helix are required for full 
activity (Table 2). The smallest truncation, which 
removes the 3’-terminal 16 nucleotides of RNA10.2, 
causes a four-fold loss in the second-order rate of inacti- 
vation. Additional truncations, down to 42 nucleotides, 
cause only incremental additional losses of inhibitory 
activity. Comparable results were obtained for 
0.00 ’ I I I 
0 25 50 75 100 
Added [Na+], m M  
Fig. 8. Irreversible inhibition of hNE by selected RNA:DNA:valP com- 
plexes is highly salt-sensitive. 0 No inhibitor; W  RNAl0.6:DNA:valP; 
0 RNA1 0.11 :DNA:valP. Elastase inhibition assays were performed as 
described in Materials and methods, and in the legend to Figure 4. The 
concentration of RNA:DNA:valP assemblies was 50 nM. The amount of 
Na+ added to Hank’s balanced salt solution (HBSS) is indicated on the 
x-axis; HBSS is 137 m M  Na+, 5 m M  K+. 
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Fig. 9. The RNA:DNA:valP double helix is stable at the experi- 
mental temperature. Melting curves of RNA:DNA:valP com- 
plexes are shown. (a) Normalized absorbance curves. Red, 
RNA1O.l I; blue, RNAWN7.1. (b) Determination of T,,, values. 
Data from (ai were replotted as the first derivative of (transmit- 
tance) I with respect to temperature. The peaks of these plots 
correspond to the T,,, values 1281. Assignment of the sharper 
peaks at 51 “C (RNA40N7.1, blue), and 58 “C iRNAlO.l 1, red) to 
the RNA-DNA:valP double helices was made by titrating in 
Increasing amounts of the DNA:valP oligonucleotide. 
RNA1 0.1 1 (Table 2). Thcsc rrwlts indicate th‘tt strut- 
tul-cs iniportant for inhibitory activity xc dimibuted 
throughout the aelmcd llNA sequc~~ccx 
Inhibition of tissue damage by human neutrophils 
Hurn~n neutrophil clastase is intplicawd it1 J nunlh 
of iti~ldtiiiiidt~~t-). distxec; highly 5prcific md potent 
inhibitors xc usetul in cl,lrifying the role of hNE in 
dise‘tw. We uwd ,tii 0s IJ~IV pet-t~twd t-at lung svstwt to test 
the ability of the itlhibitors to protect 1Lings ti-oni ititer- 
leukitt- 1 (I la-l) induced, I~UIILIII neutt-ol’hil-medi,ited 
d.ttii,igr. Lxge .tc~utilulatiotl\ of neutrophils are found 
in lung IJVJ~C of Al<I>S p,ttient$. md ‘tre \tt-ongl) 
itttplic‘md in the pthogene~i~ ofAl<l>S [ IX, IO]. lL-1 is 
.~lso found .It rlev,tted levels in lung lav~gcc of ARl>S 
pttietits. .tnd induces neutrophil ,tccutnulxion and lung 
lc,tli iti rats 1201. 
It1 the rdt lung tiiodel, IO” human neutrophils arr circw 
latcd through isolated, ventildted lung5 in 30 ml of 
buffewd perfits:itr, ,tnd al ARl>S-like inflatntnator~ 
Table 2. Effects of 3’ truncations on hNE inactivation. 
RNA RNA length0 nt removed kinact app/K,, M-’ min-’ 
10.2 71/O 5.6 x 10” 
10.2.55 5.5116 1.4 x 106 
10.2.47 47124 1.2 x 106 
10.2.42 42129 I .I) x 106 
10.11 71/o 2.4 x 10” 
10.1 1.49 49122 9.1 x IO” 
10.11.40 4013 I 5.9 x 10” 
The indicated RNA sequences were annealed to the DNA:valP 
splint, and hNE inactivation assays were performed as 
described in Materials and methods. Truncated RNAs were pro- 
duced by using synthetic DNA oligonucleoticles whose i’ ends 
correspond to the desired 3’ terminus as PCR primers on the 
full-length template. Double-stranded DNA products of the 
appropriate length were purified by gel electrophoresis, and 
used as templates for transcription. nt, nucleotides. 
rcspotise is induced by intra-trachrdl ddtninistratioti of 
IL-l 12 1.321. The resulting inflanunxor): rt’spnw per- 
turbs lung tissue, lc,lding to edcnlCt-like weight g,tin (Fig. 
10, espt I vs 2), which is titeasured dfter one hour. 
Adding 30 pm01 (0.5 pg) of the RNA10.1 1 :I~NA:vnlI’ 
assetiibly to the perfusate before IL- I adtiiitiistt-‘ttion 
decreases tt~utrophil-tnediated weight gain (Fig. 10, espt 
1). The reduction in lung weight pin cotnparcd to ,I 
positive control is highly significant (Fig,. 10. expt 1 v\ 4, 
P<O.O(11) using the Studettt-Ne\l-nlvl-I<eulc tnultiplc 
comparison test; \ceight piti is not sigtiific,ttitlv grcatct- 
than the negatiw control (Fig. 10, expt 2 vs 1. b&.0.3). 
Adding only the RNA 10. I 1 :l>NA:v~ll’ assctttbly to the 
system does not cauw lung mC$t gain (Fig. 10. txpt 3). 
Control experiments 5how that the protecttw effect is 
mediated prima-ily by hNE itt~~ctivation; RNA 10.1 1 
without the l~NA:v~ll~ splint. \vhich is not cspcctcd to 
inhibit hNE at the lmv concentrntion used, does tlot 
reduce lung xveight gain (Fig. IO, c’xpt 5 (eqt 3 vs 5, 
P<(l.OOi)). Similarly, the I)NA:\all’ y>lint Jonc is not 
effective (Fig. IO, c’spt 6 (cxpt 3 vs 6. P<O.OOl)). III t~ity~ 
experiments with the full RNA 10.1 1 :I>NA:vall’ ,twn- 
bly show th‘tt nentt-ophil viabilit); chettlotx4s. ,tnd super- 
oxide production drc utinffected by the inhibitor (d,tt,t 
not \ho\\n) Thccc rccults su ggcst tlut tiigjily specific and 
potent irtmwsible inhtbttors of hNE IIJV~‘ thrr,tpeutic 
potentiJ in the treatment of AI<l>S, and po~sihly in 
other ticutt-ol’hil-mediated ititl,itiitii3tor). diw.ws. 
Significance 
The blending of combinatorial and medicinal 
chemistries is a drug discovery strategy aimed 
at fusing the strengths of both approaches. 
Medicinal chemistry requires a large amount 
of labor to screen a relatively small number of 
compounds. Combinatorial chemistry selects 
from a large number of compounds, but usually 
only on the basis of affinity to a target, with- 
out reference to desirable functional properties 
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Expt #: 1 2 3 4 5 6 
IL-l+PMN + 0 0 + + + 
RNA1O.ll 0 0 + + + 0 
DNA:valP 0 0 + + 0 + 
Fig. 10. The RNAlO.ll:DNA:valP complex has a protective 
effect in the human neutrophil-perfused rat lung model of 
ARDS. 1 O6 PMN (neutrophils), and 20pmol of each nucleic acid 
were used in each experiment. Bars show the mean of n experi- 
ments, error bars indicate one standard error. The level of signifi- 
cance in comparison to the positive control using the 
Student-Newman-Keuls multiple comparison test is P  < 0.001 
for experiments 2, 3 and 4; not significant for 5 and 6. 
[l-5]. The incorporation of a functional moiety 
into a combinatorial library greatly increases 
the likelihood that the winning sequences will 
have desirable properties. Conversely, one can 
think of this blended approach as a method to 
obtain highly active and highly specific variants 
of a small molecule. The ability to ‘build-in’ 
a desirable function is a feature that distin- 
guishes SELEX from strategies such as phage 
display or generation of monoclonal antibodies. 
The blending of medicinal and combinatorial 
chemistries is a general strategy in drug discov- 
ery and development, which can be applied to a 
wide range of small molecules and libraries, 
accelerating the search for compounds that will 
advance disease treatment. 
These principles are demonstrated by the elastase 
inhibitors generated through blended SELEX; the 
inhibitors are much more potent and specific than 
the valyl phosphonate moiety alone. These 
inhibitors are shown to be highly efficacious at low 
doses in an isolated, perfused rat lung model of 
ARDS. A dose of 0.5 pg in 30 ml of perfusate is 
sufficient to abolish neutrophil-mediated lung 
weight gain, without affecting neutrophil viability, 
motility or adherence. 
Finally, we note that the blended SELEX strat- 
egy may be applied to other fields, such as the 
investigation of RNA-based catalysis. In particu- 
lar, the suggestion that modified nucleotides 
acted as catalytic cofactors in an RNA world 
[23] might be fruitfully studied using a blended 
SELEX approach. 
Materials and methods 
Synthesis of the co-ligand for human neutrophil elastase 
The diphenylphosphonovaline co-ligand 3 may be synthe- 
sized from the known benzyl carbamate-protected 
diphenylphosphonovaline 1 as outlined m  Figure 11. 
Condensation of isobutyraldehyde, benzyl carbamate (Cbz) 
and triphenylphosphite gave compound 1 in 55 !?4 yield. The 
Cbz group was removed with 30% HBr/AcOH and the 
resulting HBr salt converted to the free amine 2 in 86% 
overall yield.Treatment of compound 2 with ,W,N’-disuccin- 
imidyl carbonate (DSC) in acetonitrile provides the desired 
co-ligand 3 which may be conjugated to the amino-DNA 
splint via the Mhydroxy succinimide (NHS) ester moiety. 
Synthesis of N -benzyloxycarbonyl-O,O’- diphenyl- 
phosphono-valine (compound I) 
Benzyl carbamate (30.23 g, 0.20 mol), isobutyraldehyde (27.25 
ml, 0.30 mol) and triphenylphosphite (52.4 ml, 0.20 mol) were 
dissolved in 30 ml  of glacial acetlc acid in a 250 ml  round- 
bottom flask.After stirring at room temperature for 5 min, the 
solution was heated to 80-85 “C in an oil bath for 3 h. The 
1) HBdAcOH 
- H\ Tl 8 0 DSC 
p, OPh c 0 AX /p 2) NH,(g). Et20 N-O H OPh CH,CN ‘I’ 7‘ OPh H OPh 
2 
0 
3 
Fig. 11. Scheme for synthesis of inhibitor. 
For details see Materials and methods. 
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mixture mas concentrated to an oil on a rotary evaporator 
equipped with a vacuum pump and using a bath temperature 
of 90-YS “C. The oil was subsequently dissolved in 250 ml  of 
boiling methanol, filtered and chilled to -15°C to promote 
crystallization. The crystalline colid was filtered, washed with 
cold methanol. air dried and then dried overnight in a vacuum 
deGccator to give 18.2g (55%) of the product. 
Synthesis of O,O’-diphenylphosphonovaline (compound 21 
RTBenzyloxy-carbonyl-O,O’-diphenylhosphonovaline (21.97 
g, 50.0 mmol)  \vac treated with 18 ml  of 30% HBr/HOAc. 
After 1 h, the solidified reaction mixture was suspended in 25 
ml  of glacial acetic acid and concentrated to an orange solid. 
The solid was triturated with 5Oml of ether overnight, 
filtered and washed with ether until off-white. A  total of 
17.5 g (91 %I) of the HBr salt was obtained.This salt wa? sus- 
pended in 15Oml of ether and gaseous ammonia bubbled 
through the suspension for 15 min.The ammonium bromide 
WJ\ filtered off and washed with ether. The filtrate was con- 
celltratcd and the solid residue dried under vacuum to give 
13.05 g (86% overall) of the desired free amine 2. 
Synthesis of N-succinimidyloxycarbonyl-O,O’-diphenyl- 
phosphonovaline (compound 3) 
,~,N’-L)isucciniIilidyl carbonate (213 mg, 0.95 mrnol) way 
dissolved in 5 ml  of dry acetonitrile. A  solution of O,O’- 
diphcnylphosphonovalinc (289 mg, 0.95 mmol)  in 3 ml  of dr) 
acetorntrilc was added and the mixture stirred at room tem- 
perature for 2h. The precipltnted product was filtered, 
\vashed with dry acetonitrile and dried under vacuum to 
give 22Y mg (51%) of a white solid. 
Coupling of valyl phosphonate diphenyl ester to 
splint DNA 
The splint DNA is a synthetic oligonucleotide (sequence 
shown in Fig. 3) that contains a hexylamine (2-methyl 
h)droxyl) linker at the 5’ phosphate (Operon).To couple the 
\ralyl phosphonate diphenyl ester to the splint DNA, 200 nmol 
of DNA \vas dissolved in 500 ~1 DMSO plus 50$ 0.5M 
NaHO,, pH Y.0, and then added to 5.2mg of the NHS ester of 
the valyl pho5phonate, 3, allowed to react at room temperature 
for 1 h, then ethanol precipitated. The oligonucleotide was 
rc\uspended in 200 p,l of H,O, then purified by reverse-phace 
HPLC in a gradient of aceto~iitrile:triethylamine acetate. 
SELEX 
For the hNE reaction, 20-1l)Opmol SELEX RNA at a conceIl- 
tration of 1 F M  was annealed to a 1. l-fold excess of splint 
DNA:valP by heating to 65 “C and cooling slowly to 35 “C.The 
reaction was initiated by adding hNE to a final concentration of 
S-2OnM, at a 5- to 2%fold excess of RNA over hNE. After 
incubation for 5-l 0 min at 37 “C, the reaction was quenched by 
adding SDS to 0.1 ‘%I. 
The j21r, RNA:L>NA:valP:hNE complexes were resolved from 
unrcacted “P RNA:l>NA:valP by electrophoresis through a I’%  
polyacrylamidc gel containing TBE and 0.05 o/u SDS, and then 
recovered from the gel by the crush-and-soak method.This RNA 
was amplified by reverse transcription, PCR and transcription by 
T7 RNA polymerase. essentially as described 1241. 
Individual sequences were cloned by blunt-end ligation of PCR 
L>NA into vector ‘PCR-script SK+’ (Stratagene), and transfor- 
mation into ‘Epicurian Competent SURE Cells’ (Stratagene). 
DNA cequrnces were obtained by enzynlatic sequencing. 
Elastase activity and inhibition assays 
Elastasc substrate (I+methoxysuccinyl Ala-Ala-Pro-Val 
p-nitroanilide,AAPV-pNA, Calbiochem) at 0.2 or 0.3nlM was 
mixed with inhibitor at the indicated concentration in 0.2 ml  
Hank’s balanced salt solution (HBSS), 25mM Tris, pH 7.5, 
0.01 ‘$4 human serum albumin, in a microtiter plate well at 
37 “C. The reaction was initiated by adding hNE 
(Calbiochem), and absorbance at 405nm was monitored in a 
BioTek EL312 microtiter plate reader. The data were tit 
(Kaleidagraph, Synergy Software) to the following equation: 
where vci is the mltlal rate of peptide hydrolysis, kobr ,ndCt is the 
observed rate of inactivation, and A, is a displacement factor. 
This equation describes the behavior of an inhibitor that Ini- 
tially binds to the enzyme reversibly to attain a rapid equilib- 
rium, and subsequently reacts with first-order kinetics to 
inactivate the enzyme [25,26].The rapid equilibrium assump- 
tion was tested by continuous monitoring of the colorigenic 
reaction of hNE with AAPV-NA. When 50nM of the 
RNA10.11:DNA:valP complex was added to an ongoing 
reaction, the slope of the A,,,, versus time plot was deflected 
instantly, within the limits of detection (<5s, data not shown). 
k 
The apparent second-order rate constant of mactivation, 
111.1N1 ,,,,,, 
K, 
was obtained by replotting kob, ,ndCf as a function of inhibitor 
concentration, and determining the slope of the least-squares 
linear regression. To correct for competition between elastase 
substrate and inhibitor, the true second-order rate of n- 
activation was calculated usmg a model of full competitive 
inhibition [27]: 
1 + [AAPV ~ ~NA] 
K  
The value used for K, AAPV-pNA is 1OOmM. Salt-sensitivity 
experiment5 were performed m  HBSS, 25mM Tris, pH 7.5, 
0.01 %  human serum albumin, with O-100 m M  NaCl added. 
Covalent reaction with hNE 
Splint DNA:valP was radiolabeled at the 3’ end with 321’ 
cordycepin (New England Nuclear) and terminal deoxy- 
nucleotide transferase (Promega), and then annealed with 
RNA in HBSS. 25 m M  Tris, pH 7.5.The reaction was initiated 
by adding a 23-fold excess of hNE at a series of concentrations 
at 37°C. Two to five aliquots were withdrawn at a range of 
t ime points, and quenched with two volumes of 10 M  urea, 1 O/I 
SDS. Reaction extent was limited to 120% of the total DNA. 
“P DNA:valP:hNE complexes were resolved from free 32P 
l>NA:valP by electrophoresis through 10% polyacrylamide gels 
with 7 M  urea, 0.05% SDS. The relative amount of 31P 
DNA:valP conjugated to hNE was quantified using a Fujix 
BASlOOO Phosphorimager. 
The apparent first-order rate constant, koby, was determined 
from the slope of a plot of ln(S,&,) versus time, where S, is 
the amount of unreacted j2P splint DNA:valP remaining at a 
given time, and S,, ir the initial amount, corrected for the 
fraction of active compound, determined by extended reac- 
tions. The value of kobr was replotted as a function of hNE 
concentration, and titted to the Michaelis-Menten equation 
to obtain k,,, and K, for the covalent reaction of the splint 
DNA:vall’ with hNE. 
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Thermal melts 
The buffer used for thermal melting experiments \vac HHSS 
yupplcmented with 20mM HEPES, pH 7.5, purged bvith He 
gas and filtered. Measurements wet-c made in a temperature- 
controlled Cary 1E UV-Vis spectrophotomcter. RNA (typt- 
tally 12 /J& and DNA:vnlP were added to 2.lml of buffer 
which W~P then pre-melted by heating front i “C to 95 “C at a 
rate of 12 OC min -‘. then cooled to 5 “<I and held. Melting 
curves were obtained by heating from 5 “C to 95 “C at a rate of 
1 “<: minm’ The absorbance at 200 nn, was recorded at 0.2 tnin 
Intervals. Repeated melting curves on the same sample showed 
no evidence of hysteresis. 
Isolation and perfusion of lungs 
After Sprague&>awley adult male rats (350 5 5Og) were dues+ 
thetized with pentobarbital (60 mg kg-‘, i.p.), a tracheotomy 
cannula was placed and secured with 2-O ligature. Lungs were 
ventilated with a tidal volume of 3 cc at a rate of 60 min- with 
a gas mixture containing 5% CO,, 21 ‘96 0, and 74% N,. 
Following midline thoractomy, a 1-O ligature was loosc~y 
placed around the root of the pulmonary outtlo\v tract. Heparin 
(2OOunits) was then injected into the right ventricle and 
allowed to recirculate. A  rtgtd cannula was subsequently placed 
into the right ventricle, threaded into the pulmonary outflow 
tract, and secured with the ligature. The left ventricle \V;IS 
incised next and a drainage cannula was inserted and secured 
with a 2-O ligature. Lungs and heart were excised, placed in an 
isolated lung chamber, and vcntilnted with 2.5 cm of positive- 
end expiatory pressure. Lungs were perfused free of blood using 
Earlc’s balanced salt solution (Sigma Chemical Co.) containing 
(g 1-l) 0.265 calcium chloride. 0.098 magnesium sulfate, 0.4 
potassium chloride. 6.X sodium chloride, 0.122 sodium phos- 
phate monobasic, and 1 II-glucocc to which was added 2.2 g I-’ 
sodium bicarbonate and IC)g 1-l Ficoll-70 (Sigma Chemical 
Co.), and the final pH adjusted to 7.40. l’erfuratc (3Oml) \vas 
passed through the lungs to remove residual blood.The system 
was then closed and 30 ml  of perfusatc was continuously re- 
circulated at a rate of 4Oml kg-’ body weight minm’. l’ultttonat-) 
artery pressures were continuously monitored with a pressure 
transducer and weight increaTes were monitored with a force 
transducer. A  26min equilibration period m~t.s follo~ved by .I 
60 min experimental protocol. 
Purification of human neutrophils 
Heparinized blood was obtained from healthy volunteers. 
Neutrophils were isolated using a Percoll gradient and differ- 
ential centrifugation. Each preparation contained highly puri- 
fied (~99 %) neutrophils which were suspended in HBSS at a 
concentration of 2x 10’ m m ’. 
Afkr~ou,le~‘~emcrlrr: We thank J. Reed for skillful assistance with 
HPLC purification, and B. I’olisky and L. Gold for critical 
reading of the manuscript. 
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